Home

Crestline SI (GP), L.P.

CIK 1626597 · last filed 2021-02-17

Crestline SI (GP), L.P. is a corporate insider who has filed 2 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing shows the insider sold $720.5M of DNLI on Feb 17, 2021. Across all open-market trades the lifetime net is −$642.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.1M across reported positions. The firm reports its address in Fort Worth, TX. 11 SEC filings were submitted jointly with DOUGLAS K BRATTON.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.11M

Companies

2

Total Filings

2

Lifetime Open-Market Net

-$642.33M

Filer Profile

Reported Address
C/O CRESTLINE INVESTORS, INC.
201 MAIN STREET, SUITE 1900
FORT WORTH, TX 76102
Phone
(817) 339-7600
State of Incorporation
DE
Related Filers
DOUGLAS K BRATTON — 11 joint filings, latest 2021-02-17
Crestline Investors, Inc. — 11 joint filings, latest 2021-02-17
Crestline Management, LP — 11 joint filings, latest 2021-02-17
CL Alaska, L.P. — 5 joint filings, latest 2017-07-17
Bratton Capital Inc. — 2 joint filings, latest 2017-12-14
Bratton Capital Management, L.P. — 2 joint filings, latest 2017-12-14
Neuro Line Partners LP — 2 joint filings, latest 2017-12-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DNLI 10%+ Owner 100,102 $21.09 $2.11M -$720.46M 1 2021-02-17
Juno Therapeutics, Inc. (JUNO) Delisted 10%+ Owner 23,488,398 — — $78.12M 1 2014-12-23

Recent Filings

2 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-02-17 DNLI Sell (S) −11,083,990 -$720.46M EDGAR
2014-12-23 Juno Therapeutics, Inc. (JUNO) Delisted Mixed +133,605,635 $78.12M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.